Status:
NOT_YET_RECRUITING
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Lead Sponsor:
Laboratoires Thea
Conditions:
Moderate to Severe Vernal Keratoconjunctivitis
Eligibility:
All Genders
4-17 years
Phase:
PHASE2
Brief Summary
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
Eligibility Criteria
Inclusion
- Main
- Informed consent signed and dated
- Male or female participant from 4 years to less than 18 years old.
- Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye.
- Main
Exclusion
- Participants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.
Key Trial Info
Start Date :
March 2 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 21 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT07169695
Start Date
March 2 2026
End Date
January 21 2027
Last Update
September 12 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.